Intranasal LAIV Mucosal Immunity Examination

Conditions

• Impact of Vaccination

Eligibility Criteria

Sex

ALL

Age

2 Years - 89 Years

Healthy Volunteers

Accepted

Interventions

• Live Attenuated Influenza Vaccine — BIOLOGICAL
  Nasal spray

Study Details

The research of the investigators is focused on the understanding how the immune system functions and responds to intranasal vaccines. Intranasal vaccines do not lead to the same changes in the blood that intramuscular vaccines do. Therefore, the investigators want to look at the function of immune (lymphoid) organs that are near the nose. The closest immune organs are the adenoids and tonsils. Mice do not have tonsils allowing for the investigators to answer these questions. Human lymphoid tissue will allow the investigators to better understand the molecular behavior of these cells in humans. The purpose of this protocol is to administer the FDA approved live attenuated influenza vaccine or no vaccine to patients undergoing adenoidectomy and/or tonsillectomy for obstructive sleep apnea prior to surgery and then collect the tissue (adenoid and/or tonsil tissue) that would normally be discarded from surgery. This will allow for improved understanding of what happens after vaccination.

Key Dates

Start date

Feb 28, 2026

Status verified

Dec 2025

Primary completion

Apr 30, 2026

Completion

Jul 31, 2026

Study Design

Enrollment

25 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Arms

• Experimental: Interventional LAIV
  Intranasal Flu Vaccine
• No Intervention: No Intervention
  No Intervention

Primary Outcome Measure

Serological outcomes will be compared before and after vaccination and between groups. [ Time Frame: From enrollment to 4 weeks after surgery is completed ]

Locations (1)

Find similar trials in Baltimore, MD